NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals

Document Type : Review Article

Authors

1 Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran,

2 Virology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran,

3 Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran,

4 Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran,

5 Lung Transplant Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran,

6 Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran,

7 Department of Clinical Immunology and Infectious Diseases, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran,

8 Research Center for Neurosurgery and Functional Nerves, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

In December 2019, the first case of coronavirus disease 2019 (COVID-19), was reported from China. An emerging infectious disease caused by a new strain of coronavirus, namely severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to a global health problem and pandemic (1).
By 28 May 2020, the total number of laboratory-confirmed cases of COVID-19 surpassed 5,701,337, with 357,688 reported deaths worldwide (2). Iran reported its first confirmed cases of COVID-19 on the 19 February 2020 in Qom, Qom Province (3), and by 29 May 2020, a total of 143,849 confirmed cases and 7627 deaths were reported (2).